No Data
No Data
Express News | Aprea Therapeutics: Under Terms of Agreement, Aprea Will Retain All Rights, Title, and Interest in Apr-1051
Express News | Aprea Therapeutics Announces Agreement With Md Anderson Cancer Center to Explore Apr-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (Hnscc)
Aprea Therapeutics Expands IP Portfolio For DNA Damage Response Cancer Treatments
Express News | Aprea Therapeutics Announces Strategic Ip Portfolio Evolution in DNA Damage Response (Ddr) Cancer Therapeutics
Strategic Advancements and Financial Stability Drive Buy Rating for Aprea Therapeutics
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $20